Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities.

Genes, chromosomes & cancer - 1 Jan 2026

Li Xuetao, Ye Meifeng, Huang Xiaomei, Huang Zhong-Yin, Zhu Juan, He Zipeng, Zhao Zhuxiang, Hou Jun, Wei Shuquan

Abstract excerpt

BACKGROUND: Although TP53 and RB1 co-alterations play critical roles in promoting malignant development and progression, specific inhibitors targeting this co-alteration are lacking. We performed a pan-cancer analysis to characterize the biology of TP53/RB1 co-alterations and identify therapeutic strategies. METHODS: We analyzed mutation data and copy number variation (CNV) data from 42 371 pan-cancer samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Copy Number Variations
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KMT2D gene

Share to Mutation

Share to Neoplasms

Share to Retinoblastoma Binding Proteins

Share to Tumor Suppressor Protein p53

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 41562186
DOI: 10.1002/gcc.70100
PMCID: PMC12820914

Genes

RB1
TP53
AURKA
APC
ARID1A
CREBBP
EGFR
KMT2D
KRAS
PIK3CA
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities.PMID 41562186Read ↗

A Pan-Cancer Assessment of RB1/TP53 Co-MutationsSemantic proximity Read ↗

Cancer-Type Specific Prognostic Impact of Concurrent TP53 and KRAS Alterations: A Multi-Cohort Genomic AnalysisSemantic proximity Read ↗

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read ↗

Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome AtlasSemantic proximity Read ↗

Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of TumorigenesisSemantic proximity Read ↗

Characterizing genomic differences of human cancer stratified by the TP53 mutation status.Semantic proximity Read ↗

Co-occurring genomic alterations and immunotherapy efficacy in NSCLCSemantic proximity Read ↗

Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.Semantic proximity Read ↗

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.Semantic proximity Read ↗

Decoding the Most Mutated Genes in Cancer: a Pan-cancer in Silico Analysis of DLBC, CHOL, UCSSemantic proximity Read ↗

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapySemantic proximity Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.